PMID- 25688060
OWN - NLM
STAT- MEDLINE
DCOM- 20151203
LR  - 20231111
IS  - 1179-6901 (Electronic)
IS  - 1174-5886 (Print)
IS  - 1174-5886 (Linking)
VI  - 15
IP  - 1
DP  - 2015 Mar
TI  - mTOR: a potential therapeutic target in osteoarthritis?
PG  - 27-36
LID - 10.1007/s40268-015-0082-z [doi]
AB  - Osteoarthritis (OA) is a chronic degenerative joint disease characterized by the 
      progressive loss of articular cartilage, remodeling of the subchondral bone, and 
      synovial inflammation. Mammalian target of rapamycin (mTOR) is a serine/threonine 
      protein kinase that controls critical cellular processes such as growth, 
      proliferation, and protein synthesis. Recent studies suggest that mTOR plays a 
      vital role in cartilage growth and development and in altering the articular 
      cartilage homeostasis as well as contributing to the process of cartilage 
      degeneration associated with OA. Both pharmacological inhibition and genetic 
      deletion of mTOR have been shown to reduce the severity of OA in preclinical 
      mouse models. In this review article, we discuss the roles of mTOR in cartilage 
      development, in maintaining articular cartilage homeostasis, and its potential as 
      an OA therapeutic target.
FAU - Pal, Bandna
AU  - Pal B
AD  - Division of Genetics and Development, The Toronto Western Research Institute, 
      Toronto Western Hospital, The University Health Network (UHN), 60 Leonard Avenue, 
      Toronto, ON M5T 2S8 Canada.
FAU - Endisha, Helal
AU  - Endisha H
AD  - Division of Genetics and Development, The Toronto Western Research Institute, 
      Toronto Western Hospital, The University Health Network (UHN), 60 Leonard Avenue, 
      Toronto, ON M5T 2S8 Canada.
FAU - Zhang, Yue
AU  - Zhang Y
AD  - Division of Genetics and Development, The Toronto Western Research Institute, 
      Toronto Western Hospital, The University Health Network (UHN), 60 Leonard Avenue, 
      Toronto, ON M5T 2S8 Canada.
FAU - Kapoor, Mohit
AU  - Kapoor M
AD  - Division of Genetics and Development, The Toronto Western Research Institute, 
      Toronto Western Hospital, The University Health Network (UHN), 60 Leonard Avenue, 
      Toronto, ON M5T 2S8 Canada.
AD  - Department of Surgery, University of Toronto, Toronto, ON Canada.
AD  - Division of Orthopaedics, Toronto Western Hospital, Toronto, ON Canada.
LA  - eng
GR  - 201003/Canadian Institutes of Health Research/Canada
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Review
PL  - New Zealand
TA  - Drugs R D
JT  - Drugs in R&D
JID - 100883647
RN  - EC 2.7.11.1 (TOR Serine-Threonine Kinases)
SB  - IM
MH  - Animals
MH  - Disease Models, Animal
MH  - Gene Deletion
MH  - Humans
MH  - Mice
MH  - *Molecular Targeted Therapy
MH  - Osteoarthritis/*drug therapy/genetics/physiopathology
MH  - Severity of Illness Index
MH  - TOR Serine-Threonine Kinases/*antagonists & inhibitors/genetics
PMC - PMC4359178
EDAT- 2015/02/18 06:00
MHDA- 2015/12/15 06:00
PMCR- 2015/02/17
CRDT- 2015/02/18 06:00
PHST- 2015/02/18 06:00 [entrez]
PHST- 2015/02/18 06:00 [pubmed]
PHST- 2015/12/15 06:00 [medline]
PHST- 2015/02/17 00:00 [pmc-release]
AID - 82 [pii]
AID - 10.1007/s40268-015-0082-z [doi]
PST - ppublish
SO  - Drugs R D. 2015 Mar;15(1):27-36. doi: 10.1007/s40268-015-0082-z.